Adjuvant chemoradiation therapy for pancreas cancer: Who really benefits?

Advances in Surgery

Volumn 44, Issue 1, 2010, Pages 149-164

  Merchant, Nipun B ^a   Parikh, Alexander A ^a   Liu, Eric H ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; CANCER REGISTRY; HUMAN; MORTALITY; PANCREAS TUMOR; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEER PROGRAM; TREATMENT OUTCOME;

EID: 77956164651     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yasu.2010.05.019     Document Type: Review

References (46)

1. American Cancer Society Cancer Facts and Figures 2008 [internet]. Atlanta, GA: ACS; 2008. Available from Accessed May 11, 2010. http://www.cancer.org.
2. Golcher H., Brunner T., Grabenbauer G., et al. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol 2008, 34(7):756-764.
3. Kim H.J., Czischke K., Brennan M.F., et al. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?. J Gastrointest Surg 2002, 6(5):763-769.
4. Tse R.V., Dawson L.A., Wei A., et al. Neoadjuvant treatment for pancreatic cancer-a review. Crit Rev Oncol Hematol 2008, 65(3):263-274.
5. Greer S.E., Pipas J.M., Sutton J.E., et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 2008, 206(3):451-457.
6. Katz M.H., Wang H., Fleming J.B., et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009, 16(4):836-847.
7. Lowy A.M. Neoadjuvant therapy for pancreatic cancer. J Gastrointest Surg 2008, 12(9):1600-1608.
8. Kalser M.H., Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120(8):899-903.
9. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230(6):776-782. [discussion: 782-4].
10. Neoptolemos J.P., Kerr D.J., Beger H., et al. ESPAC-1 trial progress report: the European randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer. Digestion 1997, 58(6):570-577.
11. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358(9293):1576-1585.
12. Neoptolemos J.P., Stocken D.D., Friess H., et al. A Randomized Trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350(12):1200-1210.
13. Neoptolemos J.P., Stocken D.D., Tudur S.C., et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009, 100(2):246-250.
14. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297(3):267-277.
15. Neuhaus P., Riess H., Post S., et al. CONKO-001: Final Results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC) [abstract]. J Clin Oncol 2008, 26(Suppl 20). LBA4504.
16. Regine W.F., Winter K.A., Abrams R.A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299(9):1019-1026.
17. Neoptolemos J, Büchler M, Stocken DD, et al. ESPAC-3(v2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. Presented at the American Society of Clinical Oncology Annual Meeting, Orlando (FL), June, 2009.
18. Van Laethem JL, Mornex F, Azria D, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: updated results of a randomized EORTC/FFCD/GERCOR phase II study (40013-22012/9203). Presented at the American Society of Clinical Oncology Annual Meeting, Orlando (FL), June, 2009.
19. Nukui Y., Picozzi V.J., Traverso L.W. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2000, 179(5):367-371.
20. Picozzi V.J., Kozarek R.A., Traverso L.W. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003, 185(5):476-480.
21. Linehan D.C., Tan M.C., Strasberg S.M., et al. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg 2008, 248(2):145-151.
22. Herman J.M., Swartz M.J., Hsu C.C., et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008, 26(21):3503-3510.
23. Corsini M.M., Miller R.C., Haddock M.G., et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the mayo clinic experience (1975-2005). J Clin Oncol 2008, 26(21):3511-3516.
24. Cameron J.L., Riall T.S., Coleman J., et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006, 244(1):10-15.
25. Yeo C.J., Cameron J.L., Sohn T.A., et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997, 226(3):248-257. [discussion: 257-60].
26. Greco J, Castaldo E, Feurer I, et al. Survival benefit with adjuvant radiation therapy in surgicall resected pancreatic cancer. Preseted at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando (FL), January 2007.
27. Merchant N.B., Rymer J., Koehler E.A., et al. Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits?. J Am Coll Surg 2009, 208(5):829-838. [discussion: 838-41].
28. Picozzi V.J., Pisters P.W., Vickers S.M., et al. Strength of the evidence: adjuvant therapy for resected pancreatic cancer. J Gastrointest Surg 2008, 12(4):657-661.
29. Cheng T.Y., Sheth K., White R.R., et al. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol 2006, 13(1):66-74.
30. Lowy A.M., Lee J.E., Pisters P.W., et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 1997, 226(5):632-641.
31. Spitz F.R., Abbruzzese J.L., Lee J.E., et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997, 15(3):928-937.
32. Abrams R.A., Lowy A.M., O'Reilly E.M., et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009, 16(7):1751-1756.
33. Picozzi V.J. Today's forecast for the Adjuvant Treatment of Pancreatic Cancer: clear or cloudy? Oncology 2007, 21(6).
34. Katz MH, Merchant NB, Brower S, et al. Standardization and documentation of surgical and pathologic variables in a multi-institutional trial of adjuvant therapy for pancreatic cancer: results from ACOSOG Z5031, presented at Gastrointestinal Cancers Symposium. Orlando (FL), January 2010.
35. Yeung R.S., Weese J.L., Hoffman J.P., et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. a phase II study. Cancer 1993, 72(7):2124-2133.
36. Staley C.A., Lee J.E., Cleary K.R., et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996, 171(1):118-124. [discussion: 124-5].
37. Hoffman J.P., Lipsitz S., Pisansky T., et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998, 16(1):317-323.
38. Pisters P.W., Abbruzzese J.L., Janjan N.A., et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998, 16(12):3843-3850.
39. Pisters P.W., Wolff R.A., Janjan N.A., et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002, 20(10):2537-2544.
40. White R.R., Kattan M.W., Haney J.C., et al. Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. Ann Surg Oncol 2006, 13(11):1485-1492.
41. Moutardier V., Magnin V., Turrini O., et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2004, 60(2):437-443.
42. Mornex F., Girard N., Scoazec J.Y., et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 phase II trial. Int J Radiat Oncol Biol Phys 2006, 65(5):1471-1478.
43. Talamonti M.S., Small W., Mulcahy M.F., et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006, 13(2):150-158.
44. Palmer D.H., Stocken D.D., Hewitt H., et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007, 14(7):2088-2096.
45. Evans D.B., Varadhachary G.R., Crane C.H., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26(21):3496-3502.
46. Varadhachary G.R., Wolff R.A., Crane C.H., et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26(21):3487-3495.